Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world’s population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal...
Guardado en:
Autores principales: | David Blánquez-Martínez, Xando Díaz-Villamarín, Alba Antúnez-Rodríguez, Ana Pozo-Agundo, José Ignacio Muñoz-Ávila, Luis Javier Martínez-González, Cristina Lucía Dávila-Fajardo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4adc7064e37c439eaf52b26c7a335386 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
por: S. A. Korotkikh, et al.
Publicado: (2016) -
Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis D, et al.
Publicado: (2017) -
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019) -
Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
por: Zhuang Cui, et al.
Publicado: (2021) -
Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
por: Singer M, et al.
Publicado: (2020)